Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

August 25, 2020 0

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis (EXEL) announced the submission of …

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

August 25, 2020 0

The US FDA Awards Fast Track Designation to Paxalisib for Glioblastoma Kazia Therapeutics Ltd (KZIA) – an …

What’s Going on with Gene Therapy?

August 25, 2020 0

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas …

The FDA’s Complete Response Letters, Creating Investment Opportunities?

August 20, 2020 0

Yesterday, under Today’s Highlights, we posted that the U.S. FDA issued a Complete Response Letter (CRL) …

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

August 19, 2020 0

Gilead Sciences Was Issued a CLR from the FDA for Filgotinib Gilead Sciences (GILD) is in …

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

August 17, 2020 0

CureVac is Publicy Trading on the NASDAQ CureVac is now publicly trading on the NASDAQ stock …

An Important Announcement from Sorrento Therapeutics

August 13, 2020 0

Sorrento Therapeutics Announcement Sorrento Therapeutics (SRNE) announced that it believes it has uncovered fraudulent attempts to …

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

August 13, 2020 0

A Predictive COVID-19 Test? COVID-19 infected people are not all affected to the same degree with …

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

August 11, 2020 0

Intellia Therapeutics Reporting operational highlights and financial results for the second quarter ended June 30, 2020, Intellia …

Seres Therapeutics Oral Microbiome Product SER-109 Meets Trial Endpoint

August 10, 2020 0

Seres Therapeutics Oral Microbiome Product SER-109 for Recurrent C. Difficile Infection Meets Trial Endpoint SER-109 demonstrated …

Alterity Therapeutics: Treating Neurodegenerative Diseases?

August 5, 2020 0

When a small firm’s stock price soars, and more than doubles, curiosity pushes us to investigate. …

Regenxbio: Positive One-Year Data from the Firm’s Gene Therapy RGX-314 for Wet AMD

August 4, 2020 0

Regenxbio Positive Data for RGX-314 Regenxbio (RGNX) reported positive one-year data from patients in Cohorts 4 …

Compugen: A Stock To Keep

August 3, 2020 0

Compugen Compugen (CGEN) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint …

Inovio: Good News About the Firm’s COVID-19 Vaccine’s Capability and Durability

July 30, 2020 0

Inovio Inovio’s COVID-19 Vaccine INO-4800 Accomplished the Following: Durable antibody and T cell responses in rhesus …

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

July 30, 2020 0

Edesa Biotech Filed an IND for EB05 Edesa Biotech (EDSA), a clinical-stage biopharmaceutical company, has filed …

Moderna News. See Also: Regeneron Antibody Cocktail Could Reach the Market in October

July 29, 2020 0

SARS-CoV-2 Virus Vaccines Moderna On Monday Moderna (MRNA) started its Phase 3 clinical trial on 30,000 …

The FDA Approved Gilead Sciences CAR T Cell Product Tecartus for Adults with Relapsed or Refractory Mantle Cell Lymphoma

July 27, 2020 0

Gilead Sciences CAR T Cell Product Tecartus Gets FDA Approval The U.S. FDA approved Kite - …

TCR2 Therapeutics Encouraging Oncology Results

July 27, 2020 0

TCR2 Therapeutics Announcement TCR2 Therapeutics (TCRR) – a clinical-stage immunotherapy company with a pipeline of novel T cell therapies …

Could Arbutus Biopharma’s Patent Harm Moderna?

July 24, 2020 0

Arbutus Biopharma and Moderna's Patent Challenge Arbutus Biopharma (ABUS) is a publicly-traded biopharmaceutical company dedicated to …

Jazz Pharmaceuticals: A New FDA Approval

July 22, 2020 0

People living with narcolepsy who develop cataplexy and excessive daytime sleepiness have a new treatment called Xywav, …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

What’s Going on with Gene Therapy?

The FDA’s Complete Response Letters, Creating Investment Opportunities?

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

An Important Announcement from Sorrento Therapeutics

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

Seres Therapeutics Oral Microbiome Product SER-109 Meets Trial Endpoint

Alterity Therapeutics: Treating Neurodegenerative Diseases?

Regenxbio: Positive One-Year Data from the Firm’s Gene Therapy RGX-314 for Wet AMD

Compugen: A Stock To Keep

Inovio: Good News About the Firm’s COVID-19 Vaccine’s Capability and Durability

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

Moderna News. See Also: Regeneron Antibody Cocktail Could Reach the Market in October

The FDA Approved Gilead Sciences CAR T Cell Product Tecartus for Adults with Relapsed or Refractory Mantle Cell Lymphoma

TCR2 Therapeutics Encouraging Oncology Results

Could Arbutus Biopharma’s Patent Harm Moderna?

Jazz Pharmaceuticals: A New FDA Approval